Kanaph Therapeutics Inc
0082N0
Company Profile
Business description
Kanaph Therapeutics Inc is a biotech company dedicated to developing anticancer drugs and ophthalmic disease treatments based on human genome-based drug development technology. Its core technology lies in identifying novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and in developing drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs, based on these findings. The groups pipeline products are KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701.
Contact
3, Itaewon-ro 55ga-gil
5th Floor, Golden Nugget
Yongsan-gu
Hannam-dong
Seoul
KORT: +82 27989438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
stocks
Major ASX miner remains overvalued following production update
Iron ore strength keeps production on track despite lower copper output.
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
From Google Cloud to Gemini user retention, here’s what we expect from Alphabet’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.90 | 33.40 | 0.37% |
| CAC 40 | 8,345.51 | 5.40 | 0.06% |
| DAX 40 | 24,902.40 | 55.71 | 0.22% |
| Dow JONES (US) | 51,839.26 | 307.16 | -0.59% |
| FTSE 100 | 10,546.54 | 21.78 | 0.21% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,508.07 | 12.17 | -0.05% |
| Nikkei 225 | 66,232.19 | 2,091.07 | 3.26% |
| NZX 50 Index | 13,656.03 | 40.00 | -0.29% |
| S&P 500 | 7,443.28 | 14.41 | -0.19% |
| S&P/ASX 200 | 8,793.30 | 36.30 | 0.41% |
| SSE Composite Index | 3,864.37 | 68.09 | 1.79% |